[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2121553T3 - Fremgangsmåde til fremstillingen af terapeutisk værdi-fulde triphenylbutenderivater - Google Patents

Fremgangsmåde til fremstillingen af terapeutisk værdi-fulde triphenylbutenderivater

Info

Publication number
DK2121553T3
DK2121553T3 DK08718510.4T DK08718510T DK2121553T3 DK 2121553 T3 DK2121553 T3 DK 2121553T3 DK 08718510 T DK08718510 T DK 08718510T DK 2121553 T3 DK2121553 T3 DK 2121553T3
Authority
DK
Denmark
Prior art keywords
buten
triphenyl
derivatives
procedure
fully
Prior art date
Application number
DK08718510.4T
Other languages
English (en)
Inventor
Marja Soedervall
Maire Eloranta
Arja Kalapudas
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Application granted granted Critical
Publication of DK2121553T3 publication Critical patent/DK2121553T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/30—Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08718510.4T 2007-02-14 2008-02-13 Fremgangsmåde til fremstillingen af terapeutisk værdi-fulde triphenylbutenderivater DK2121553T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88983807P 2007-02-14 2007-02-14
PCT/FI2008/050057 WO2008099059A1 (en) 2007-02-14 2008-02-13 Method for the preparation of therapeutically valuable triphenylbutene derivatives

Publications (1)

Publication Number Publication Date
DK2121553T3 true DK2121553T3 (da) 2012-07-23

Family

ID=39271403

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08718510.4T DK2121553T3 (da) 2007-02-14 2008-02-13 Fremgangsmåde til fremstillingen af terapeutisk værdi-fulde triphenylbutenderivater

Country Status (19)

Country Link
US (2) US7812197B2 (da)
EP (3) EP2518039B8 (da)
JP (1) JP5363344B2 (da)
KR (1) KR101510646B1 (da)
CN (1) CN101636372B (da)
AU (1) AU2008214530B2 (da)
BR (2) BRPI0807675B1 (da)
CA (1) CA2677861C (da)
CY (1) CY1113184T1 (da)
DK (1) DK2121553T3 (da)
ES (3) ES2389961T3 (da)
HK (2) HK1139379A1 (da)
HR (1) HRP20141107T1 (da)
MX (1) MX2009008660A (da)
PL (1) PL2121553T3 (da)
PT (1) PT2121553E (da)
RU (1) RU2465261C2 (da)
SI (2) SI2518039T1 (da)
WO (1) WO2008099059A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2518039B8 (en) * 2007-02-14 2014-12-17 Forendo Pharma Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US9085519B2 (en) * 2010-01-19 2015-07-21 Cambrex Karlskoga Ab Processes for producing benzophenone derivatives
KR101308258B1 (ko) * 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2909164A1 (en) 2012-10-19 2015-08-26 Fermion Oy A process for the preparation of ospemifene
EP2909163A1 (en) 2012-10-19 2015-08-26 Fermion Oy A process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
CN104788300B (zh) * 2014-01-22 2017-01-11 南京华威医药科技开发有限公司 欧司哌米芬多晶型
CN104230723B (zh) * 2014-08-21 2016-08-24 凯莱英医药集团（天津）股份有限公司 托瑞米芬的合成方法
WO2016043189A1 (ja) * 2014-09-16 2016-03-24 塩野義製薬株式会社 トリフェニルブテン誘導体の製造方法
US9975832B2 (en) 2014-12-29 2018-05-22 Olon S.P.A. Process for the preparation of ospemifene and fispemifene
WO2016110805A1 (en) * 2015-01-09 2016-07-14 Glenmark Pharmaceuticals Limited Process for preparation of ospemifene
CA3016545A1 (en) * 2016-03-15 2017-09-21 Shionogi & Co., Ltd. Method for producing phenoxyethanol derivative
KR20240041745A (ko) 2022-09-23 2024-04-01 김민정 입체음향 베개

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2641075C2 (de) * 1975-09-29 1985-11-14 The Regents Of The University Of California, Berkeley, Calif. Verfahren zur Herstellung von symmetrischen Olefinen
JPS5422313A (en) * 1977-07-22 1979-02-20 Kougai Boushi Chiyousa Kenkiyu Process for preparing nnformylamine
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
ATE130293T1 (de) 1990-10-01 1995-12-15 Univ Texas Tamoxifenderivate mit hoher affinität und ihre verwendung.
US6096874A (en) 1990-10-01 2000-08-01 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5352699A (en) * 1992-04-30 1994-10-04 University Of Massachusetts Medical Center Use of retinioc acid to treat vaginal atrophy
US5446203A (en) * 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
FI100692B (fi) 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5658931A (en) * 1994-09-20 1997-08-19 Eli Lilly And Company Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
EP0794771A1 (en) * 1994-11-29 1997-09-17 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
GB9509572D0 (en) 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5747059A (en) * 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
GB9604577D0 (en) * 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
DE19653736C2 (de) * 1996-12-12 2002-11-21 Lancaster Group Gmbh Kosmetisches Präparat mit Peptidzusatz
GB9803521D0 (en) 1998-02-19 1998-04-15 Orion Yhtymo Oy New compounds and pharmaceutical compositions thereof
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6525084B2 (en) * 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CA2395730A1 (en) 2000-01-28 2001-08-02 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6514898B2 (en) * 2000-12-15 2003-02-04 Shell Oil Company Process of preparing a fluid rare earth alkoxylation catalyst
FI111710B (fi) * 2001-05-04 2003-09-15 Hormos Medical Oy Ltd Menetelmä terapeuttisesti aktiivisen yhdisteen valmistamiseksi
WO2003015820A1 (fr) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
ATE418972T1 (de) 2001-11-29 2009-01-15 Gtx Inc Verhinderung und behandlung von durch androgenmangel induzierter osteoporose
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
KR100991157B1 (ko) 2002-06-06 2010-11-02 호르모스 메디칼 리미티드 여성의 위축 억제 또는 위축관련 증상 치료 또는 예방 방법
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
EP1727802A1 (en) * 2004-02-25 2006-12-06 Smithkline Beecham Corporation Substituted quinoline compounds for use as selective estrogen receptor modulator
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
CA2578852A1 (en) 2004-09-03 2006-03-09 Hormos Medical Corporation Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
EP2518039B8 (en) 2007-02-14 2014-12-17 Forendo Pharma Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives

Also Published As

Publication number Publication date
CY1113184T1 (el) 2016-04-13
AU2008214530A1 (en) 2008-08-21
ES2590262T3 (es) 2016-11-21
EP2518039B8 (en) 2014-12-17
EP2518039A9 (en) 2013-02-13
PL2121553T3 (pl) 2012-11-30
CN101636372B (zh) 2013-03-27
EP2821385A2 (en) 2015-01-07
WO2008099059A1 (en) 2008-08-21
ES2524002T3 (es) 2014-12-03
JP5363344B2 (ja) 2013-12-11
US7812197B2 (en) 2010-10-12
CA2677861C (en) 2015-05-19
EP2518039A1 (en) 2012-10-31
HRP20141107T1 (hr) 2015-01-02
BRPI0807675B1 (pt) 2021-05-18
BRPI0823326A2 (pt) 2013-10-15
BRPI0807675A2 (pt) 2011-09-13
BRPI0823326B1 (pt) 2021-06-29
EP2821385A3 (en) 2015-02-25
ES2389961T3 (es) 2012-11-05
AU2008214530B2 (en) 2012-04-26
US20080207956A1 (en) 2008-08-28
HK1206003A1 (zh) 2015-12-31
HK1139379A1 (en) 2010-09-17
EP2121553A1 (en) 2009-11-25
SI2121553T1 (sl) 2012-11-30
EP2518039B1 (en) 2014-08-27
EP2821385B1 (en) 2016-07-27
JP2010518150A (ja) 2010-05-27
CN101636372A (zh) 2010-01-27
RU2465261C2 (ru) 2012-10-27
SI2518039T1 (sl) 2015-02-27
RU2009134131A (ru) 2011-03-20
US20110015448A1 (en) 2011-01-20
CA2677861A1 (en) 2008-08-21
PT2121553E (pt) 2012-07-26
KR20090110862A (ko) 2009-10-22
KR101510646B1 (ko) 2015-04-10
EP2121553B1 (en) 2012-06-27
MX2009008660A (es) 2009-10-13
US8293947B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
DK2121553T3 (da) Fremgangsmåde til fremstillingen af terapeutisk værdi-fulde triphenylbutenderivater
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK2231565T3 (da) Fremgangsmåder til fremstilling af clorerede carbonhydrider
SMT201600254B (it) Procedimento per la preparazione di idromagnesite
DK2155838T3 (da) Fremgangsmåde til fremstilling af forgrenede carbonhydrider
DK3301074T3 (da) Fremgangsmåde til fremstilling af aluminiumphosphat
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK2150275T3 (da) Ande-embryoniske afledte stamcellelinjer til fremstillingen af virale vacciner
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2462116T3 (da) Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser
DK2381965T3 (da) Modulation af præ-mrna under anvendelse af splejsningsmodulerende oligonukleotider som terapeutiske midler til behandling af sygdom
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2310437T3 (da) Fremgangsmåde til kontinuerlig fremstilling af polyestere
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2146944T3 (da) Fremgangsmåde til fremstillingen af 18f-mærkede folater
DK2513063T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-/1-aryl-5-pyrazolcarboxylsyrederivater
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2462098T3 (da) Fremgangsmåde til fremstillingen af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
DK2124946T3 (da) Anvendelse af N-methylpyridiniumderivater til hepatobeskyttelse